{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:49:11Z","timestamp":1788461351267,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Efgartigimod alfa, approved for treating generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive, has uncertain long-term safety in large populations This study analyzed adverse events (AEs) linked to efgartigimod alfa using data from the FDA Adverse Event Reporting System (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected and analyzed efgartigimod alfa-related reports from the FAERS database from the first quarter of 2022 through the second quarter of 2024. Disproportionality analysis was used in data mining to quantify efgartigimod alfa-related AE signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,040 reports with efgartigimod alfa as the primary suspect and 12,487 AEs were retrieved from FAERS. The most frequently reported serious outcome was hospitalization (53.22%), and death occurred in 270 cases (8.88%). Disproportionality analysis detected 137 AE signals, with the most common in nervous system disorders (22.69%), general disorders and administration site conditions (16.90%), and infections and infestations (14.05%). Notably, in addition to infection-related AEs identified during clinical trials, this study detected unexpected signals, including inappropriate schedule of product administration (ROR 2.60, PRR 2.53, IC 1.34, EBGM 2.53) and nephrolithiasis (ROR 8.13, PRR 7.99, IC 2.99, EBGM 7.95). The median onset time of AEs was 81.0\u00a0days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study provides a comprehensive assessment of the post-marketing safety of efgartigimod alfa and highlights the need for continued vigilance regarding infection-related adverse events. Additionally, the detection of inappropriate schedules of product administration underscores the importance of enhanced training and pharmacist involvement in medication management. Further research is warranted to explore the potential association between efgartigimod alfa and nephrolithiasis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1510992","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:26:19Z","timestamp":1744781179000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"16","author":[{"given":"Yunlin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J. Clin. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fimmu.2014.00408","article-title":"The role of FcRn in antigen presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","article-title":"Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group","volume":"274","author":"Bates","year":"1995","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/cnd.0000000000000377","article-title":"Current and upcoming treatment modalities in myasthenia gravis","volume":"23","author":"Beladakere Ramaswamy","year":"2021","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/bmjqs.2009.039693","article-title":"Effects of a clinical pharmacist service on health-related quality of life and prescribing of drugs: a randomised controlled trial","volume":"20","author":"Bladh","year":"2011","journal-title":"BMJ Qual. Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/s0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front. Drug Saf. Regul."},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"894685","DOI":"10.3389\/fphar.2022.894685","article-title":"Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS","volume":"13","author":"Feng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/mus.26919","article-title":"Update on immune-mediated therapies for myasthenia gravis","volume":"62","author":"Habib","year":"2020","journal-title":"Muscle Nerve"},{"key":"B14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod alfa in generalised myasthenia gravis: a profile of its use","volume":"37","author":"Heo","year":"2023","journal-title":"CNS Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2.112","DOI":"10.1136\/jnnp-2022-abn2.2","article-title":"Long-term assessment of efgartigimod in patients with generalised myasthenia gravis: ADAPT+ study interim results","volume":"93","author":"Jacob","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/14740338.2023.2189698","article-title":"Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs)","volume":"22","author":"Jain","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/PTS.0b013e3182948a69","article-title":"A new, evidence-based estimate of patient harms associated with hospital care","volume":"9","author":"James","year":"2013","journal-title":"J. Patient Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1574886318666230228142856","article-title":"Identification of signal of clindamycin associated renal failure acute: a disproportionality analysis","volume":"19","author":"Javed","year":"2024","journal-title":"Curr. Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2146\/ajhp070522","article-title":"Unit-based clinical pharmacists\u2019 prevention of serious medication errors in pediatric inpatients","volume":"65","author":"Kaushal","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis","volume":"271","author":"Li","year":"2024","journal-title":"J. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"20420986241228119","DOI":"10.1177\/20420986241228119","article-title":"Harmonization of individual case safety reports transmission requirements among PAHO reference authorities: a review of their current regulation","volume":"15","author":"Lomeli-Silva","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1097\/js9.0000000000001719","article-title":"Risk factors for nephrolithiasis formation: an umbrella review","volume":"110","author":"Ma","year":"2024","journal-title":"Int. J. Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","article-title":"Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"6","author":"Omar","year":"2021","journal-title":"ESMO Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/ju.0000000000001336","article-title":"The microbiome of catheter collected urine in males with bladder cancer according to disease stage","volume":"205","author":"Oresta","year":"2021","journal-title":"J. Urol."},{"key":"B30","year":""},{"key":"B31","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/bmj.320.7237.768","article-title":"Human error: models and management","volume":"320","author":"Reason","year":"2000","journal-title":"BMJ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eururo.2012.03.052","article-title":"Prevalence of kidney stones in the United States","volume":"62","author":"Scales","year":"2012","journal-title":"Eur. Urol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1241524","DOI":"10.3389\/fphar.2023.1241524","article-title":"Commentary: adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"14","author":"Schilder","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e28671","DOI":"10.1002\/jmv.28671","article-title":"Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms","volume":"95","author":"Sharma","year":"2023","journal-title":"J. Med. Virol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00345-017-2008-6","article-title":"Epidemiology of stone disease across the world","volume":"35","author":"Sorokin","year":"2017","journal-title":"World J. Urol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"B39","doi-asserted-by":"publisher","first-page":"104398","DOI":"10.1016\/j.critrevonc.2024.104398","article-title":"Safety of immune checkpoint inhibitors: an updated comprehensive disproportionality analysis and meta-analysis","volume":"200","author":"Tyagi","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/jci97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","article-title":"Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management","volume":"19","author":"Vanoli","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to generate antibody-based therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/archinte.165.12.1363","article-title":"Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch. Intern Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/bju.13828","article-title":"Prevalence of kidney stones in China: an ultrasonography based cross-sectional study","volume":"120","author":"Zeng","year":"2017","journal-title":"BJU Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/pathogens12060817","article-title":"Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an FcRn blocker","volume":"12","author":"Zhou","year":"2023","journal-title":"Pathogens"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1510992\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:26:20Z","timestamp":1744781180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1510992\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":47,"alternative-id":["10.3389\/fphar.2025.1510992"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1510992","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1510992"}}